Ironwood Pharmaceuticals Reports Strong Q1 Earnings and Revenue Growth

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported a strong first-quarter performance for fiscal year 2026 with significant revenue growth driven by LINZESS. The company also saw improved profitability, reduced expenses, and positive net income after reporting losses in the prior-year period.

By Laiba Immad Wed, May 20, 2026 at 11:42 PM GMT+3 2 min read · Yahoo Finance · May 20, 2026, 20:42 UTC

Ironwood Pharmaceuticals Reports Strong Q1 Earnings and Revenue Growth

Tickers: $IRWD

Topics: pharmaceuticals profitability improvement revenue growth small-cap stocks

Read the full article at Yahoo Finance

More World news

Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC
Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC
Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC